Abstract
One of the holy grails of modern medicine is choosing the right drug for the right patient. In this issue of the BJD, Wu et al. present their search for predictive serum biomarkers in patients with atopic dermatitis (AD) treated with dupilumab.1 Treatment options for moderate-to-severe AD have evolved since registration of the first biologic, dupilumab, in 2017. Currently, there are two biologics and three Janus kinase inhibitors registered for the treatment of moderate-to-severe AD. Although this new armamentarium fills a high unmet need, success in choosing the right drug for the right patient remains elusive. Currently, treatment decisions in patients eligible for advanced systemics are largely based on expert opinion and patient preferences, such as preferred route of administration (e.g. oral vs. subcutaneous). This often results in a trial-and-error approach and unnecessary exposure of patients to drugs that are not effective, and may result in side-effects. In addition, it leads to inefficient use of expensive drugs in an era of exponentially increasing healthcare expenses. Predictive biomarkers have the potential to optimize treatment response, minimize side-effects and ultimately reduce healthcare costs.